Abstract
The pathophysiological response following spinal cord injury (SCI) is
characterized by a complex cellular cascade that limits regeneration.
Biomaterial and stem cell combination therapies have shown synergistic
effects, compared to their interventions independent of each other, and
represent a promising approach towards regaining function after injury.
In this study, we combine our polyethylene glycol (PEG) cell delivery
platform with lentiviral-mediated overexpression of the
anti-inflammatory cytokine interleukin (IL)-10 to improve embryonic day
14 (E14) spinal progenitor transplant survival. PEG tubes loaded with
lentivirus encoding for IL-10 were implanted immediately following
injury into a mouse SCI hemisection model. Two weeks after tube
implantation, mouse E14 spinal progenitors were injected directly into
the integrated tubes, which served as a soft substrate for cell
transplantation. Together, the tubes with the IL-10 encoding lentivirus
improved E14 spinal progenitor survival, assessed at two weeks
post-transplantation (four weeks post-injury). Mice receiving IL-10
lentivirus-laden tubes had on average 8.1% of E14 spinal progenitors
survive compared to 0.7% in mice receiving transplants without tubes,
an 11.5-fold difference. Surviving E14 spinal progenitors gave rise to
neurons when injected into tubes. Additionally, axon elongation and
remyelination was observed, in addition to a faster rate of functional
recovery in mice receiving anti-inflammatory tubes with E14 spinal
progenitor delivery. This system affords increased control over the
transplantation microenvironment, offering the potential to improve stem
cell-mediated tissue regeneration.
Keywords: spinal cord injury, neural stem cells, biomaterials,
gene delivery, tissue engineering
Introduction
Spinal cord injury (SCI) is an incredibly devastating condition that can
leave patients both physically and financially burdened for the
remainder of their lives. Approximately 12,500 new cases of traumatic
SCI are reported annually in North America alone, with lifetime
healthcare costs averaging about $2.35 million per patient (Alizadeh,
Dyck, & Karimi-Abdolrezaee, 2019). Difficulties in treating SCI arise
as both the innate and adaptive immune responses attempting to protect
the spinal cord from further damage. The immune response, while
necessary for removing dead cells and debris, creates an inhospitable
milieu characterized by a cascade of cellular and biochemical signals,
highlighting a delicate balance between neuroplasticity and further
damage. Known as the secondary injury, this induced damage persists
through acute, sub-acute, and chronic stages of injury, spanning hours
to months post-SCI (Dalamagkas, Tsintou, Seifalian, & Seifalian, 2018;
Donnelly & Popovich, 2008; Dumont, Margul, & Shea, 2016) resulting in
glial and fibrotic scarring (Bradbury & Burnside, 2019; Hackett & Lee,
2016; Soderblom et al., 2013; Zhu, Soderblom, Trojanowsky, Lee, & Lee,
2014), axonal dieback and demyelination (Busch, Horn, Silver, & Silver,
2009; Hill, 2017), apoptosis (X. Z. Liu et al., 1997), and oxidative
stress (Hall, 2011) severely limiting regenerative potential.
Exogenous stem cell transplantation is a promising technique that is
highly dependent on the transplantation microenvironment. Cell
transplantations have shown initial promise both broadly in tissue
engineering (Kwon, Kwon, Lee, Park, & Kim, 2018) and specifically in
SCI repair models (Dulin & Lu, 2014). On a cellular level, neural stem
cell (NSC) transplants repopulate lost neural and glial cells in damaged
tissue (Dulin & Lu, 2014; Mortazavi et al., 2015) in addition to
working on a molecular level through cytokine and chemokine release
post-SCI (P. Lu, Jones, Snyder, & Tuszynski, 2003). Furthermore,
transplanted NSCs can integrate with endogenous neural circuitry (Ceto,
Sekiguchi, Takashima, Nimmerjahn, & Tuszynski, 2020; Kumamaru et al.,
2018) and can significantly decrease local expression of
pro-inflammatory cytokines (Cheng et al., 2016). Altogether, NSCs
exhibit numerous pro-regenerative functions that are highly contingent
on cell survival post-transplantation. Transplantation method, medium,
location, and cell age all play pivotal roles in influencing survival
(Chen, Bernreuther, Dihné, & Schachner, 2005; Karimi-Abdolrezaee,
Eftekharpour, Wang, Morshead, & Fehlings, 2006; Nagoshi et al., 2018),
but perhaps the most important factor to consider with cell therapies is
their transplantation microenvironment. In SCI, NSC delivery is
complicated by the persisting secondary injury. As the immune response
clears damaged cells and cell debris, transplanted cells are also
subjected to inhospitable conditions, leading to poor survival and
limited regenerative effect. SCI cell transplantation strategies
commonly delay delivery to occur after an initial wave of post-injury
inflammation (Tetzlaff et al., 2011). Starting hours after injury,
inflammatory cytokines including interleukin (IL)-1β, tumor necrosis
factor α (TNFα), IL-6, and leukemia inhibitory factor (LIF) are strongly
activated in the wound area, but their concentrations decrease by 1 week
post-injury. Similarly, reactive oxygen species peak in concentration
approximately 12 hours after injury, but by 1 week post-injury, their
concentration drops precipitously (Donnelly & Popovich, 2008; Dumont et
al., 2016; Lacroix, Chang, Rose-John, & Tuszynski, 2002; Shamash,
Reichert, & Rotshenker, 2002). Avoiding these inflammatory mediators by
delaying transplantation has the potential to improve survival, but
further intervention is required for cell transplants to have their
intended regenerative effects.
Biomaterial interventions have proven to be effective following SCI in
shifting the post-injury microenvironment and improving regeneration
(Shuo Liu, Xie, & Wang, 2019; Straley, Foo, & Heilshorn, 2010) making
them promising candidates to be used in combination therapies with stem
cell transplants (Shengwen Liu, Schackel, Weidner, & Puttagunta, 2018;
Shrestha et al., 2014) where the goal is to create a more hospitable
transplantation environment to improve transplant survival. Highly
porous, polymeric scaffold implants can facilitate regeneration in the
spinal cord, where the porosity allows for endogenous progenitor
infiltration, aiding in axonal regrowth and myelination (Pawar et al.,
2015; Shahriari, Koffler, Tuszynski, Campana, & Sakamoto, 2017; Straley
et al., 2010; Tuinstra et al., 2012; Tuinstra et al., 2013; Y. Yang et
al., 2009). Furthermore, implantable scaffolds provide a defined
architecture that directs axonal elongation. Softer, hydrogel based
implants fabricated from polyethylene glycol (PEG) microspheres have
also proved to support regeneration (Dumont et al., 2019). Macroporous
tubes, molded from PEG microspheres, function similar to rigid,
polymeric scaffolds, but are advantageous in that they better match
native tissue mechanical properties and have the potential to conform to
individual injury anatomy. Biomaterial strategies for SCI can
additionally support stem cell transplantation whether that is throughex vivo culture on a rigid scaffold (Dumont et al., 2018; Li et
al., 2016; Mothe, Tam, Zahir, Tator, & Shoichet, 2013), suspension in
hydrogel injections (Assunção-Silva, Gomes, Sousa, Silva, & Salgado,
2015; Cai, Dewi, & Heilshorn, 2015; Marquardt & Heilshorn, 2016), or
direct injection into an integrated implant (Ciciriello et al., 2020).
Alone, biomaterials passively modify immune cell infiltration and
inflammation, resulting in improved stem cell survival
post-transplantation, but a more active role in immune modulation can be
taken through delivery of an anti-inflammatory factor.
Lentiviral vectors are a highly effective method for active therapeutic
treatment with presently ongoing clinical trials (Milone & O’Doherty,
2018). Lentivirus-mediated therapies work by integrating within a host
genome, resulting in long-term overexpression of the selected gene of
interest. Implantable biomaterials can serve as a medium for loading and
release of lentivirus, and this has been investigated heavily in both
SCI models (Abdellatif et al., 2006; Boehler et al., 2014; Daniel J.
Margul et al., 2016; Park, Decker, Margul, et al., 2018; Park, Decker,
Smith, et al., 2018; Dominique R. Smith et al., 2020; D. R. Smith et
al., 2019) and for other tissue engineering applications like islet
transplantation (Chou & Sytwu, 2009; Jimenez-Moreno et al., 2015; J. M.
H. Liu, Zhang, Joe, Luo, & Shea, 2018), cancer immunotherapies (Arce,
Breckpot, Collins, & Escors, 2011; Liechtenstein, Perez-Janices, &
Escors, 2013; Milone & O’Doherty, 2018), and cardiac tissue repair (Di
Pasquale, Latronico, Jotti, & Condorelli, 2012; Niwano et al., 2008;
Zhao et al., 2002). Lentiviral-mediated over-expression of cytokines
from the IL family, specifically those targeting macrophages, has shown
promise in altering immune response post-injury. Macrophages are a
well-studied cell population, often viewed as an attractive therapeutic
target. Infiltrating macrophages are traditionally grouped into two
general phenotype classes, pro-inflammatory M1 and pro-regenerative M2,
each with important functions post-injury. In reality, the behavior of
these phenotypes is much more nuanced than the binary options presented
here (Mosser & Edwards, 2008), but this provides a frame of reference
for distinguishing between pro-inflammatory and pro-regenerative roles.
Furthermore, this described phenotypic difference opens the opportunity
for lentiviral-mediated overexpression of an anti-inflammatory cytokine,
like IL-10, to facilitate the polarization of M1 to M2 macrophages to
create a more pro-regenerative microenvironment.
In this work, we expand the passive microenvironment modulation of our
macroporous PEG tubes to actively modify the transplantation
microenvironment through lentiviral-mediated delivery of IL-10.
Previously, we demonstrated the short-term feasibility of the temporally
flexible transplantation of enhanced green fluorescent protein
(EGFP+) embryonic day 14 (E14) spinal progenitors into
integrated PEG tubes (Ciciriello et al., 2020). Expanding on this prior
work, in our current study we will implant IL-10 encoding
lentivirus-laden tubes into a C5 lateral hemisection, and two weeks
later inject EGFP+ E14 spinal progenitors directly
into the tubes at the lesion epicenter. This two week period between
tube implantation and E14 spinal progenitor transplantation affords the
tubes time to integrate and the IL-10 encoding lentivirus to modulate
the immune response, ultimately improving transplantation. Alone, the
tubes served as a privileged cell transplantation site, so we anticipate
that adding lentivirus-mediated IL-10 delivery will further improve
transplantation survival, resulting in long term benefits in
regeneration and functional restoration through both endogenous and
exogenous repair mechanisms, marking an important step forward in the
development of a comprehensive cell delivery platform for SCI repair.
Methods
Fabrication of hydrogel tubes
Hydrogel tubes were generated as previously described (Dumont et al.,
2019). Briefly, 20% w/v 8-arm polyethylene glycol maleimide (PEG-MAL,
20 kDa; JenKem, Plano, TX) was crosslinked with 5 mM
slow-degrading-plasmin-sensitive YKND cross-linking peptide
(Ac-GCYKNDGCYKNDCG; Genscript, Piscataway, NJ) (Shikanov, Smith, Xu,
Woodruff, & Shea, 2011) to form microspheres through water-oil emulsion
with diameter ranging between 15 and 150 µm and an average of 45 µm. The
PEG-YKND solution was homogenized in silicone oil (Fisher, Hampton, NH)
with 2% Tween-20 (Sigma, St. Louis, MO) at a speed of 4000 rpm for 1
minute. Microspheres were rinsed by centrifugation three times. Irgacure
2959 photoinitiator (Sigma) dissolved in N-vinylpyrrolidinone (660
mg/mL; Sigma) was added to the microspheres at a final concentration of
1% w/v. The resulting microspheres were then packed into
polydimethylsiloxane (PDMS, Dow Corning, Midland, MI) molds to generate
PEG tubes (approximate OD: 600 μm, ID: 250 μm, porosity 66%) and
exposed to an ultraviolet lamp for 3 minutes to initiate free radical
polymerization. Tubes were rinsed three times, dehydrated, and stored at
-80 until use. Tubes were cut to length during surgery to ensure fit
within the defect.
Spinal progenitor isolation
All animal work pertaining to progenitor cell isolation was performed
with prior approval and in accordance with the Institutional Animal Care
and Use Committee (IACUC) guidelines at the University of Michigan and
University of Miami. Embryonic spinal progenitors were isolated from the
spinal cords of embryonic day 14 (E14) C57BL/6-Tg(CAG-EGFP)10sb/J mice
(Jackson Laboratory, Bar Harbor, ME), enzymatically dissociated with 10
U/mL papain (Worthington, Lakewood, NY) and 37 μg/mL DNase (Sigma) into
single cells, and expanded as neurospheres in ultralow attachment flasks
(Corning, Corning, NY), as described previously (Dumont et al., 2018).
Embryonic spinal progenitors were expanded in Dulbecco’s Modified Eagle
Medium (DMEM; Gibco, Grand Island, NY) supplemented with 1X B27 (Gibco),
1X N2 (Gibco), N-acetyl cysteine (NAC; Sigma), and 20 ng/mL basic
fibroblast growth factor (FGF2; Peprotech, Rocky Hill, NJ) and leukemia
inhibitory factor (LIF; Peprotech). E14 cell colonies were passaged with
papain as needed and not used beyond the second passage for
transplantation studies.
Production of lentiviral vectors
Lentivirus was produced as described previously (D. R. Smith et al.,
2019). HEK-293FT cells (80-90% confluent, American Type Culture
Collection, Manassas, VA) were transfected with third generation
lentiviral packaging vectors and pLenti-CMV-Luciferase or
pLenti-CMV-hIL10. Correct insertion was validated via DNA sequencing.
Plasmids were incubated in OptiMEM (Life Technologies, Carlsbad, CA)
with Lipofectamine 2000 (Life Technologies) for 20 minutes prior to
being added to cells. After 48 hours of incubation, supernatant was
collected, centrifuged to remove cellular debris, and then incubated
with PEG-It (System Biosciences, Palo Alto, CA) for 16-24 hours at 4°C.
Virus was centrifuged at 1500g at 4°C for 30 min, supernatant was
removed, and the pellet was re-suspended in sterile phosphate buffered
saline (PBS; Life Technologies). Viral solution was aliquoted and frozen
at -80°C until use. Viral titers used throughout the study were 4E9
IU/mL as determined by the Lentivirus qPCR Titer Kit (Applied Biological
Materials, Richmond, BC, Canada). Viral vectors used in this study were
from the same batch as described by Smith et. al. (Dominique R. Smith et
al., 2020), thus all in vivo protein expression data would be
comparable between these studies. However, it should be noted that
additional vector expression analysis was performed using the In Vivo
Imaging System (IVIS; Perkin Elmer, Waltham, MA) with the
pLenti-CMV-Luciferase vector as described below.
SCI surgeries
All animal work was performed with prior approval and in accordance with
the Institutional Animal Care and Use Committee (IACUC) guidelines at
the University of Michigan. A C5 lateral hemisection SCI was created in
adult C57BL/6J female mice aged 6-8 weeks, as previously described (D.
J. Margul et al., 2016; Thomas et al., 2013; Thomas et al., 2014).
Briefly, mice were anesthetized with 2% isoflurane and provided
preemptive local pain management (1 mg/kg bupivacaine). After
confirmation of anesthesia via toe pinch, a 2 cm incision was made in
the skin to facilitate the laminectomy performed at C5. A 1.15 mm
lateral hemisection was excised in the left side of the spinal cord.
This ensures any functional deficits are confined to the left forepaw,
providing an internal control with the right paw. PEG tubes were cut to
size, allowed to dehydrate for 30 s, and implanted individually into the
injury site, which accommodated 5 tubes in total. A subset of these mice
received 2 μL of 4E9 IU/mL pLenti-CMV-hIL10 viral vector injected
directly into the tubes. Gelfoam was used to secure the injury site in
all conditions, after which the muscles were sutured and skin stapled. A
subset of mice (no-treatment control group) did not receive an implant
but did receive gelfoam over the injured spinal cord. Mice were
immediately provided post-operative antibiotics (enrofloxacin 2.5 mg/kg
once a day for 2 weeks), analgesics (0.1 mg/kg buprenorphine twice a day
for 3 days), and supportive hydration (1 mL/20 g lactated ringer
solution once a day for 5 days). Bladders were expressed twice daily
until function recovered and staples were removed after 10 days.
Surgical controls were put in place to limit lesion size variance,
including the order of the incisions made to limit the effects of
swelling to cut lines, measuring the distance between the rostral and
caudal cuts, and verifying the absence of bruising to the contralateral
tissue. Exclusion criteria include any deviations to the surgical
controls, as well as any variance to the recovery timeline, including an
inability to ambulate by post-operative day 3. No mice met these
exclusion criteria for this study.
All mice received a second surgery 14 days after the primary injury.
Protocols for anesthesia and post-operative care were the same as
described with the initial surgery. After anesthesia induction, an
incision in the skin was made, sutures in the muscle were removed, and
any remaining gelfoam was carefully removed from atop the spinal cord.
Two injections of E14 EGFP spinal progenitors (2 μL of 150,000 cells in
PBS – 300,000 cells/mouse) or PBS were injected in the rostral-medial
and caudal-lateral regions of the hydrogel implant using a 33G 10μL
Hamilton syringe at a rate of 1 μL/minute. Gelfoam was placed back over
the injury, muscles were sutured, and wound clips applied. Mice were
euthanized and spinal cord segments (C4-6) were collected after 4 or 12
weeks (2 or 10 weeks after cell transplantation). For each condition, n
= 4-12 mice at each time point: n = 4 for histology at week 4 (N=24), n
= 6 for bioluminescent imaging (N=12), n = 6 for histology at week 12
(N=36), and n = 12 for ladder beam analysis (N=72).
Bioluminescent imaging
Bioluminescent signal was evaluated with IVIS. Mice used to assess
bioluminescent signal received a single surgery, in which the injury was
made, tubes were implanted, and 2 μL of 4E9 IU/mL lentivirus with a
luciferase reporter was injected directly into the tubes. A second set
of mice did not receive the viral injection and served as controls.
Gelfoam was placed over the injury, muscles were sutured, and wound
clips applied. After 7 days the wound clips were removed. Mice were
injected with 150 mg/kg D-Luciferin (Promega, Madison, WI)
intraperitoneally 10 minutes prior to imaging. Mice were sedated 5
minutes prior to imaging and transferred to the IVIS chamber under
continuous isoflurane sedation. D-Luciferin injections and IVIS imaging
were repeated at weeks 4, 6, 8, and 12. Living Image (Perkin Elmer)
software was used to evaluate total flux based on bioluminescent signal
within the injury site.
Endogenous progenitor identification
Bromodeoxyuridine (BrdU) was used to identify proliferating cells in the
first 7 days post-SCI, as described previously (Ciciriello et al.,
2020). Intraperitoneal injections of 50 mg/kg BrdU (Roche, Basel,
Switzerland) were pulsed every day for 7 days, allowing 7 additional
days for unbound BrdU to wash out before exogenous spinal progenitors
were implanted, as done by others (Ciciriello et al., 2020; Z. Yang et
al., 2015). Using this protocol, overlap of BrdU and exogenous EGFP cell
transplants was not observed. Any cells that co-localized with BrdU and
neuronal lineage markers described below were considered to arise from
endogenous spinal progenitors giving rise to new cells along the
neuronal lineage. Tissue sections requiring BrdU identification were
first denatured in 2N HCl for 1 hour at 37 °C followed by neutralization
in 2 five minute rinses of 0.1M borate buffer to facilitate antigen
retrieval. Samples were incubated for 1 hour at room temperature in rat
anti-BrdU (1:200, Abcam, Cambridge, UK) antibody followed by appropriate
fluorophore-conjugated goat anti-rat secondary antibody before
proceeding with additional immunohistochemistry of specific cell
phenotypes described below.
Immunohistochemistry
Isolated spinal cords were flash frozen, and then cryosectioned
transversely (4 or 12 week tissue) in 12 μm sections.
Immunohistochemistry analysis was performed using nine transverse
sections evenly spaced across the rostral, middle, and caudal regions of
the tubes and average across each animal allowing for comparisons
between animals while considering regional differences (Ciciriello et
al., 2020; Dumont et al., 2019). Samples were fixed, permeabilized
(0.5% triton-X for 10 minutes) and/or prepared with BrdU staining
(described above) as necessary, and incubated overnight at 4°C with
primary antibodies. The following antibodies were used for primary
detection: rat anti-F4/80 (1:200, Abcam, Cambridge, United Kingdom),
goat anti-arginase (1:100, Santa Cruz, Dallas, TX, USA), rabbit
anti-neurofilament-200 (1:200, Sigma), goat anti-myelin basic protein
(MBP; 1:500, Santa Cruz), chicken anti-P0 (1:250, Aves Labs, Tigard,
OR), chicken anti-GFP (1:200, Aves Labs), rabbit anti-Tuj1 (1:500,
Sigma), mouse anti-NeuN (1:500, Millipore, Burlington, MA), mouse
anti-Nestin (1:200, Millipore), rabbit anti-GFAP (1:500, Thermo
Scientific, Waltham, MA), and rat anti-IL-10 (1:100, Thermo Scientific).
Species-specific fluorescent secondary antibodies were used for
detection at 1:1000 (Life Technologies, Carlsbad, CA, USA). Hoechst
33342 (Life Technologies) was used as a counterstain in all tissue
sections. Immunostained tissue sections were imaged using an
AxioObserver inverted fluorescent microscope (Zeiss, Oberkochen,
Germany) using a 10X dry objective.
Progenitor survival, proliferation, and fate:Immunohistochemistry was used to verify no overlap between
BrdU+ and EGFP+ cell types.
Subpopulations of exogenous EGFP+ cells and endogenous
BrdU+ cells were counted manually by two blinded
researchers to evaluate progenitor-driven neurogenesis. The following
cell populations were quantified: exogenous progenitors
(EGFP+BrdU-Nestin+),
endogenous progenitors
(BrdU+EGFP-Nestin+),
exogenous neuroblasts
(EGFP+BrdU-Nestin+Tuj1+),
endogenous neuroblasts
(BrdU+EGFP-Nestin+Tuj1+),
exogenous early neurons
(EGFP+BrdU-Tuj1+Nestin-),
endogenous early neurons
(BrdU+EGFP-Tuj1+Nestin-),
exogenous neurons
(EGFP+BrdU-NeuN+),
and endogenous neurons
(BrdU+EGFP-NeuN+).
Cells were quantified within the injury and normalized to the implant or
injury (empty control) area. Nine tissues evenly distributed throughout
the rostrocaudal axis of the injury were averaged for each animal.
Axon Density and Myelination: Semi-automated counting software,
previously described by McCreedy et al.(McCreedy et al., 2016), was used
to quantify axons and the co-localization of myelin with axons in
transverse sections Briefly, the software was calibrated using manual
NF-200+ (axons),
NF-200+MBP+ (myelinated axons), and
NF-200+MBP+P0+(Schwann cell myelinated axons) counts from a subset of transverse 10X
images taken from different animals and regions of the implant. The
software then used a series of Hessian filters and threshold functions
within the bridge region to reduce noise for selected NF-200, MBP, and
P0 images (McCreedy et al., 2016). The software then output total axon
counts, as well as the myelinated axon counts based on the curvilinear
MBP co-localizing with axons with or without P0 co-localization; image
acquisition and analysis was performed by investigators blinded to
treatment condition. ImageJ (NIH, Bethesda, MD, USA) was used to analyze
all other fluorescent images and define the bridge area. Cells were
quantified within the injury and normalized to the implant or injury
(empty control) area. Nine tissues evenly distributed throughout the
rostrocaudal axis of the injury were averaged for each animal.
Immune Cell Density and Glial Scar Thickness: Cells positive for
F4/80+(macrophages) and F4/80+arginase+(M2 macrophages) containing Hoechst+ nuclei were
counted manually by two blinded researchers to quantify macrophage
infiltration. Additionally, researchers were blinded to condition during
image acquisition and quantification to eliminate bias for all
histological analyses. Cells were quantified within the injury and
normalized to the implant or injury (empty control) area. Nine tissues
evenly distributed throughout the rostrocaudal axis of the injury were
averaged for each animal. Glial scar thickness was quantified via
GFAP+ staining at the injury as previously reported
(Dumont et al., 2019). Reactive astrocytes strongly express GFAP when
forming the glial scar post-injury. Two manual thickness measurements
were averaged within each tissue, while nine tissues evenly distributed
throughout the rostrocaudal axis of the injury were averaged for each
animal.
Locomotor assessment
Ladder beam was used to evaluate mouse locomotor and coordination over a
12 week period post-SCI, as previously described for all conditions
(N=72, 12 per condition) (B. J. Cummings, Engesser-Cesar, Cadena, &
Anderson, 2007). Each of the 50 rungs were numbered and equally spaced
along the length of the beam with a dark enclosure containing bedding at
the far end of the apparatus. An HD Handycam camcorder (Sony, Tokyo,
Japan) was used to record mouse ambulation across ladderbeam. Mice were
acclimated to the ladder beam over three sessions in the two weeks
preceding the initial surgery. Baseline scores were determined to
separate animals into equal groups (tubes or gelfoam) prior to the
initial surgery. Mice were evaluated on the ladder beam every 2 weeks
over the course of the experiment. The 2 week evaluation occurred prior
to the second surgery in which the mice received spinal progenitors or
vehicle (PBS) injections. This was to allow researchers to separate
animals in equal groups prior to the addition of cell transplants.
Observation and ladder beam scoring were performed by two blinded
observers for 3 trials per animal. Animals were scored by average
forepaw full placement on the ladder beam during the task.
Statistics
Data normality was assessed using a Shapiro-Wilk normality test with an
α value of 0.05, which determined parametric statistical tests were
appropriate for our analyses. Multiple comparison pairs were analyzed
using a one-way or two-way ANOVA with Tukey post-hoc test. All
statistics test significance using an α value of 0.05. For all graphs, *
denotes p < 0.05, ** denotes p < 0.01, *** denotes p
< 0.005, and **** denotes p < 0.001, unless
otherwise specified in the figure caption. All values are reported as
mean +/- standard error of the mean (SEM). Prism 7 (GraphPad Software,
La Jolla, CA) software was used for all data analysis.
- Results
- Lentiviral expression is sustained in PEG hydrogel tubes over 12
weeks
A cohort of mice received a C5 lateral hemisection injury followed
by immediate implantation of PEG hydrogel tubes with a subsequent
injection of firefly luciferase (FLuc) encoding lentivirus directly
into the tube. A subset of these mice did not receive lentiviral
injections to serve as a background control. Bioluminescent signal
from the FLuc reporter gene was measured over 12 weeks
post-implantation to assess lentiviral expression. Lentiviral
expression of FLuc was observed in the injured area (Fig.
1A ). The average bioluminescent signal was assessed across 12 weeks
for mice receiving lentivirus and compared to those that did not
receive lentivirus (Fig. 1B ). Increased FLuc expression was
observed across the 12 weeks in lentivirus-laden PEG hydrogel tubes,
with a significant increase observed at weeks 4, 6, and 8. These
results matched lentiviral-mediated IL-10 presence at the injury
demonstrated with immunohistochemistry (Fig. S1 ). IL-10 was
strongly observed at 4 weeks post-injury in the tubes + IL-10
encoding lentivirus condition (Fig. S1A ), but there was a
noticeable drop by 12 weeks (Fig. S1B ) that coincides with
the decrease in signal measured via IVIS (Fig. 1B ).
Conversely, no IL-10 was observed at 4 (Fig. S1C ) or 12
weeks (Fig. S1D ) in the tubes alone condition.
- Macrophage infiltration is not significantly changed among
experimental groups
This study included six total conditions tested, 3 without E14
spinal progenitors (SCI, tubes, tubes + IL-10) and 3 with E14 spinal
progenitors (E14 only, E14 + tubes, E14 + tubes + IL-10). Each
individual tube has an approximate inner diameter of 250 µm and
outer diameter of 600 µm (Fig. S2A ). Upon implantation, the
tubes integrate with surrounding tissue for two weeks prior to
transplanting E14 spinal progenitors (Fig. S2B ). Four weeks
following implantation tube lumens are visible when evaluating
tissue sections transversely (Fig. S2C ), and immune cell
infiltration was quantified through F4/80 staining for macrophages
(Fig. 2A-F ). Identified F4/80+ macrophages were further
classified through arginase staining where
F4/80+arginase+ macrophages were
a pro-regenerative M2-like phenotype. No significant differences
were observed in total (Fig. 2G ) or M2-specific
(Fig. 2H ) macrophage density observed across all conditions
at 4 weeks. M2 classified macrophages were then reported as a
percent of total macrophages, and there were no significant
differences observed in M2 fraction across all conditions
(Fig. 2I ).
- Implanted hydrogel tubes attenuate glial scar thickness
Four weeks post-tube implantation, a glial scar was observed in all
conditions. The scar was quantified by measuring the thickness of the
GFAP+ astrocyte layer at the injury margin in
transversely cross-section tissue (Fig. S3A ). Formation of the
scar is important for remediating the integrity of the blood-brain
barrier, but it can also act as a physical barrier limiting axon
elongation into the injury site. Attenuation, rather than total
ablation, of the glial scar can improve functional recovery. In all mice
that received hydrogel tube implants (tubes, tubes + IL-10, E14 + tubes,
E14 + tubes + IL-10) a significant decrease in average scar thickness at
the medial interface was observed compared to both SCI only and E14
spinal progenitors only (Fig. S3B ).
E14 progenitor survival increases when combined with IL-10 encoding
lentivirus loaded hydrogel tubes
Following hemisection injury, five tubes either loaded with IL-10
encoding lentivirus or empty, were implanted into the lesion.
Additionally, an injury only condition with no tube implantation served
as a control. These mice recovered for two weeks, at which point a
second surgery was performed where mice were injected with two doses of
150,000 EGFP+ E14 spinal progenitors or PBS as a
control, delivered into the integrated tubes (Fig. 3A ). A
subset of mice (n = 4) were sacrificed after another two weeks (4 weeks
post-injury) to assess the short-term survival of transplanted E14
spinal progenitors. EGFP+ cells were observed in all
conditions receiving transplants (Fig. 3B-D ). Survival was
assessed as both a density normalized to the injury area and as a
percent of transplanted cells. E14 spinal progenitor transplantation
alone resulted in the lowest density (20.3 ± 7.5
cells/mm2) compared to E14 spinal progenitor
transplants with tubes (44.1 ± 3.7 cells/mm2) and
tubes with IL-10 encoding lentivirus (67.2 ± 19
cells/mm2) (Fig. 3E ). Similarly, mice
receiving E14 spinal progenitor transplants with no additional
treatments resulted in 0.7% of cells surviving, and those with
transplants directly into tubes had 4.3% survival. When the E14 spinal
progenitors were transplanted into IL-10 lentivirus loaded tubes, cell
survival increased to 8.1%, an 11.5-fold increase over the E14 spinal
progenitor alone condition (Fig. 3F ).
Implanted tubes support exogenous-sourced mature neuron formation by
12 weeks
Surviving transplanted E14 spinal progenitor commitment to a neuronal
lineage was assessed at both 4 and 12 weeks post-injury. At 4 weeks
post-injury (Fig. S4A-D ), no significant differences were
observed in exogenous progenitor
(EGFP+Nestin+) or neuroblast
(EGFP+Nestin+Tuj1+)
densities (Fig. S4E-F ), but there was a significant increase in
exogenous-sourced immature neurons
(EGFP+Nestin-Tuj1+)
in mice receiving E14 spinal progenitor transplants into tubes
(Fig. S4G ). No significant differences were observed in mature
neuron formation (EGFP+NeuN+) at
this early time point (Fig. S4H ). Similarly, endogenous
progenitors were quantified at 4 weeks post-injury. To label endogenous
progenitors, BrdU was injected for 7 days post-injury, followed by 7
days with no injections to allow sufficient clearance of BrdU prior to
exogenous E14 spinal progenitor transplantation. Endogenous progenitor
(BrdU+Nestin+) (Fig. S5A ),
neuroblast
(BrdU+Nestin+Tuj1+)
(Fig. S5B ), immature neuron
(BrdU+Nestin-Tuj1+)
(Fig. S5C ), and mature neuron
(BrdU+NeuN+) (Fig. S5D )
densities had no significant differences across all conditions
(Fig. S5E-H ).
Neuron formation at 12 weeks post-injury was assessed from both
exogenous and endogenous progenitor cells (Fig. 4A ). For the
conditions receiving transplanted EGFP+ E14 spinal
progenitors, neurons were identified as
EGFP+NeuN+ cells and quantified as a
density normalized to the injury cross section and as a percent of total
EGFP+ positive cells. No significant differences were
observed in EGFP+NeuN+ densities
between E14 spinal progenitors only (0.12 ± 0.1
cells/mm2), tubes with E14 spinal progenitors (1.7 ±
0.4 cells/mm2), and IL-10 lentivirus loaded tubes with
E14 spinal progenitors (1.9 ± 0.8 cells/mm2)
(Fig. 4B ). When expressed as a percent of the total
EGFP+ cells mice receiving transplanted E14 spinal
progenitors only had on average 12.8 ± 10% of their transplants form
neurons. This was significantly lower than the average percentages for
mice receiving E14 spinal progenitors with blank tubes (38.9 ± 5.1%)
and with IL-10 lentivirus loaded tubes (44.3 ± 1.7%) (Fig.
4C ). Endogenous-derived neurons were assessed as a density, and there
were no significant differences across any of the conditions tested
(Fig. 4D ).
Axon elongation increases with IL-10 lentivirus-laden hydrogel tubes
and E14 spinal progenitors
Transverse cross sections of isolated spinal cords were evaluated to
assess axon elongation in the lesion space at 12 weeks post-injury.
Facilitating and encouraging axon elongation through the injury is
crucial for any SCI treatment. Axon counts quantified using NF-200
staining were normalized to the injury area (Fig. S6 ), shown as
the solid white border (Fig. 5A-F ) to give an axon density for
each condition. Assessed samples were evenly spaced across rostral,
middle, and caudal regions of the injuries and averaged as no
significant differences in axon density were observed between individual
regions within each condition. All conditions exhibited axon elongation
into the injury (Fig. 5A-F ) at 12 weeks. Infiltrating axons
were typically observed growing in fascicle-like bundles (Fig.
5G ) or as individual, elongated structures (Fig. 5H ). Mice
receiving IL-10 lentivirus loaded tubes with E14 spinal progenitors had
significantly greater axon formation (490 ± 41
axons/mm2) compared to all other conditions. No other
significant differences were observed between conditions at this time
point (Fig. 5I ).
Axon remyelination increases with E14 spinal progenitor delivery
Elongated axons were further characterized 12 weeks post-injury by the
extent and source of their myelination to indicate functional axonal
regrowth. Myelination was quantified as a density of
NF-200+MBP+ axons normalized to the
injury area of a transverse cross section (Fig. S6 ). Mice not
receiving tubes (SCI only and E14 only) exhibited a decreased
cross-sectional area compared to the other conditions, most likely due
to tissue collapse with no support from the implanted biomaterial. All
conditions had myelinated axons present in the injury (Fig.
6A-F ). Mice receiving IL-10 lentivirus loaded tubes with E14 spinal
progenitors had 83 ± 13 myelinated axons/mm2 which was
a significantly greater density compared to the injury only control (24
± 6 myelinated axons/mm2), but they were not different
compared to any of the other experimental conditions. Similarly, the E14
spinal progenitor only condition had a significant increase in myelin
density (105 ± 12 myelinated axons/mm2) compared to
the injury only but not any of the other conditions (Fig. 6G ).
It is possible that the density calculations for the E14 spinal
progenitor only condition are artificially inflated as a result of lower
ipsilateral tissue area to normalize to, which might be attributable to
tissue collapse with no biomaterial. Ipsilateral tissue in the E14
spinal progenitor only condition was approximately 67%, 70%, and 39%
lower by comparison to tubes + IL-10, E14 + tubes, and E14 + tubes +
IL-10, respectively (Fig. S6 ). The percent of regenerated axons
was determined by normalizing the number of
NF-200+MBP+ axons to the total
number of NF-200+ axons and reported as a percent.
Mice receiving E14 spinal progenitors had a significant increase in
myelination percent compared to all other conditions tested, with 42 ±
3% of their axons having myelin. No other significant differences were
observed for myelination percent (Fig. 6H ).
Myelination source was determined where axons expressing
MBP+P0+ were identified as Schwann
cell-derived myelinated axons and
MBP+P0- were assumed to be
oligodendrocyte-derived. Both longitudinally and transversely myelinated
axons were observed in the tissue (Fig. S7A ). Mice receiving
E14 spinal progenitors alone and delivered into tubes had significant
increases in Schwann cell-derived myelinated axon densities compared to
the injury only control (Fig. S7B ). The percent of Schwann
cell-derived myelinated axons was determined by normalizing the
NF-200+MBP+P0+axons to all NF-200+MBP+ axons and
reported as a percent. The E14 spinal progenitor only condition had a
significant increase in Schwann-cell derived myelin compared to all
other conditions with 31 ± 4% of axons coming from Schwann cells
(Fig. S7C ). No other significant differences were observed.
IL-10 lentivirus loaded tubes with E14 spinal progenitors increase
rate of functional recovery
The horizontal ladder beam test assessed the functional recovery of the
left forelimb of mice at 2, 4, 8, and 12 weeks post-injury. An average
left paw placement score out of 50 possible rungs was assessed at each
time point for each condition (Fig. 7 ). At 4 weeks post-injury
the mice receiving IL-10 lentivirus loaded tubes and E14 spinal
progenitors exhibited increased function compared to the injury only
control. By 8 weeks, any combination of condition where the mice had
tubes implanted demonstrated increased function, and at 12 weeks, all
conditions had significantly more successful placements compared to the
injury only control.
Discussion
Biomaterial-based strategies are increasingly relevant in SCI tissue
engineering with numerous clinical trials investigating scaffold-based
therapies (Tsintou, Dalamagkas, & Seifalian, 2015). As a singular
therapy, biomaterial implants can promote endogenous repair mechanisms
and modulate immune responses, but combination therapies involving
biomaterials, stem cells, and therapeutic factors are more effective as
they can have therapeutic synergism, improving the potential to
facilitate repair (Ashammakhi et al., 2019). In this work, we modified
our PEG hydrogel tube platform to incorporate lentiviral-mediated
anti-inflammatory overexpression while also serving as a soft substrate
for delayed E14 spinal progenitor transplantation. Alone, the PEG tubes
are soft enough to conform to injury anatomy while maintaining an
aligned structure for axonal elongation guidance in an acute SCI (Dumont
et al., 2019). Once implanted, the tubes create a more pro-regenerative
environment, serving as a privileged injection site for E14 spinal
progenitors 2 weeks after injury. Our previous work showed that
transplanted cell survival is enhanced when injected into the tubes,
compared to direct transplantation into the injury, demonstrating the
feasibility of using this as a cell-biomaterial system for SCI
(Ciciriello et al., 2020). While survival did improve with the
integrated tubes, the stem cell-influenced results of that study were
minimized as functional and histological assessments occurred only 2
weeks after cell transplantation (4 weeks after injury). Axon elongation
and myelination were comparable between the tubes only and tubes with
E14 spinal progenitor conditions indicating the tubes played a bigger
role at this early time point. For the work presented here, we
hypothesized that adding lentivirus encoding for the anti-inflammatory
cytokine IL-10 to our implanted tubes would allow for active immune
modulation to complement the immunomodulatory properties of the
integrated tubes, further remediating the cell transplantation site.
Herein we developed a combinatorial therapy that both improved cell
transplantation survival while also exhibiting synergistic regenerative
gains at 12 weeks post-injury in an acute cervical SCI.
Lentiviral-mediated therapies present an attractive option for local
therapeutic delivery as the virus genome integrates into the host genome
and gene-of-interest expression is sustained over long periods of time
(Sakuma, Barry, & Ikeda, 2012). Moreover, lentivirus can easily be
loaded onto a biomaterial scaffold that can be implanted directly at an
injury site (Avilés & Shea, 2011; Shin, Salvay, & Shea, 2010). For
this work, we added lentivirus encoding the gene for the
anti-inflammatory cytokine IL-10 to our hydrogel PEG tubes once
implanted in an acute cervical SCI model. Previous reports have
similarly used lentiviral delivery of anti-inflammatory cytokines from
multi-channel poly(lactide-co -glycolide) (PLG) bridges in SCI
models (Park, Decker, Margul, et al., 2018; Park, Decker, Smith, et al.,
2018; Dominique R. Smith et al., 2020; D. R. Smith et al., 2019). In
these studies, rigid PLG bridges were loaded with multiple rounds of
virus ex vivo prior to implantation. Bridges loaded with IL-10
lentivirus significantly increased M2 macrophage phenotype density in
the injured region compared to control conditions demonstrating the
efficacy of lentiviral-mediated IL-10 overexpression in facilitating a
shift towards a more pro-regenerative microenvironment. For our study,
we injected IL-10 encoding lentivirus directly into our tubes
immediately after implantation to modulate the immune response after
injury and create a more hospitable microenvironment for transplanting
E14 spinal progenitors two weeks later. Macrophage phenotype was
assessed four weeks post-injury, and no significant differences across
all conditions were observed for total macrophage density or M2
macrophage density and fraction. It should be noted that mice receiving
IL-10 lentivirus injections did have a trending increase in M2 density
and fraction. Other work with IL-10 lentivirus biomaterials has shown
that the elevated M2 concentrations begin to resolve by 4 weeks
post-injury, indicating an earlier assessment point for our work would
likely show a significant increase in M2 density (Park, Decker, Margul,
et al., 2018). Additionally, our viral load was lower by comparison to
the dose used with rigid PLG bridges. Park et al. loaded their bridges
with 2 µL of 2E9 IU/mL of virus and incubating for 2 minutes to allow it
to absorb. This process was repeated three additional times for four
total doses (Park, Decker, Margul, et al., 2018; Park, Decker, Smith, et
al., 2018). By comparison, our viral loading conditions were somewhat
restricted, as the tubes are dried prior to implantation for handling
ease, and upon implantation, they swell to fit an injury. As a result,
we could not load the tubes with virus ex vivo prior to
implanting, potentially limiting the total viral load absorbed by the
bridge. Loading concentrations were restricted to a single 2 µL dose of
4E9 IU/mL, half of the total dose used by Park et al. Moving forward,
viral loading concentrations and conditions will need to be optimized in
order to observe a greater anti-inflammatory effect when used in
conjunction with stem cell transplants. Furthermore, affinity peptides
for the lentivirus can be incorporated into the hydrogel tubes to
improve their retention and localization at the injury (Skoumal,
Seidlits, Shin, & Shea, 2016).
Stem cell transplantation into the injured spinal cord is a treatment
option with high potential but has clinically been met with difficulty
in cell sourcing and scale-up (Anderson, Piltti, Hooshmand, Nishi, &
Cummings, 2017; Levi et al., 2018; Temple & Studer, 2017). In research,
another notable barrier is low survival post-transplantation, which can
largely be attributed to a cytotoxic transplantation site at the injury.
As the post-injury immune response clears out dead cells and debris, it
also targets transplanted cells, limiting their durability and potential
to promote repair (Pereira, Marote, Salgado, & Silva, 2019). Improving
exogenous cell transplant survival would allow spinal progenitors to
integrate with endogenous circuitry (Lien, Tuszynski, & Lu, 2019; Paul
Lu et al., 2017; Paul Lu et al., 2019) and remediate extracellular space
(Hawryluk et al., 2012; P. Lu et al., 2003). Biomaterial strategies have
long proven to be effective vehicles for transplanting stem cells to
central nervous system (CNS) injuries as they can be functionalized for
cell adhesion and offer a protective role against transplantation
conditions (Higuchi et al., 2019; Katoh, Yokota, & Fehlings, 2019).
Bulk biomaterial implants, like porous PLG bridges (Dumont et al., 2018)
or 3D printed scaffolds (Koffler et al., 2019), can be cultured ex
vivo with stem cells and implanted into the injury. Rigid implants with
a defined architecture also provide directional cues for axon elongation
once in the injury. Alternatively, cells can be suspended in synthetic
(Marquardt et al., 2020) or natural (Cerqueira et al., 2018; Mothe et
al., 2013) hydrogels that are soft enough to be injected and form a
biomimetic extracellular matrix once in the injury. Soft hydrogel
implants are advantageous as they better mimic the mechanical properties
of the surrounding native tissue and can swell to fit unique injury
shapes, advancing their translatability.
Unfortunately, both ex vivo culturing and hydrogel suspension
techniques for cell transplantation offer little control over delivery
time relative to biomaterial implantation as cell transplants are
dependent on the biomaterial as a carrier. The temporal dependence on
the biomaterial limits the opportunity for addressing regenerative
barriers, such as inflammation, prior to cell transplantation.
Alternatively, stem cells can be directly injected into a previously
implanted biomaterial that has had time to integrate and modulate the
immune response. In our previous report we saw approximately 4.3% of
transplanted E14 spinal progenitors survive two weeks after
transplantation when injected into integrated PEG tubes (Ciciriello et
al., 2020). For the present study, we similarly delayed E14 spinal
progenitor transplantation for 2 weeks, but we additionally incorporated
IL-10 encoding lentivirus to our PEG tubes at implantation. A buffer
period between 1 and 2 weeks is common in SCI-cell transplant strategies
(Brian J. Cummings et al., 2005; Führmann et al., 2016; Mothe et al.,
2013), and we chose 2 weeks for delaying E14 spinal progenitor delivery
to coincide with IL-10 lentivirus-attributable M2 polarization shown by
others (Park, Decker, Margul, et al., 2018). Transplant survival was
assessed after another 2 weeks, 4 weeks after tube implantation, and
8.1% of E14 spinal progenitors transplanted into IL-10 lentivirus
loaded tubes survived, an 11.5-fold difference compared to the
transplantation only control in this study. The 8.1% survival for the
E14 spinal progenitors presented here is a significant increase in
transplant engraftment compared to what has previously been demonstrated
in immunocompetent models (Tejeda, Ciciriello, & Dumont, 2021).
Combining the independent immunomodulatory properties of the tubes with
lentiviral-mediated overexpression of IL-10 resulted in synergistic
gains for the transplants, significantly improving their survival.
Exogenous NSC transplants can facilitate de novo neurogenesis,
improving regenerative potential post-SCI (Ogawa et al., 2002). We
assessed neurogenesis from surviving exogenous E14 spinal progenitors at
both 4 and 12 weeks post-injury (2 and 10 weeks post-transplantation,
respectively) using NeuN staining, a marker for mature neuron formation.
At 4 weeks post-injury, very little staining was observed for
EGFP+NeuN+ cells, indicating low
levels of neurogenesis from exogenous cells, however an observable
increase in neuronal lineage commitment was observed with Tuj staining
in EGFP+ cells transplanted with tubes or IL-10
lentivirus-laden tubes. Ogawa et al., transplanted E14.5 spinal
progenitors 9 days after a contusive injury, and they observed
neurogenesis beginning at 5 weeks post-transplantation, albeit in a rat
model (Ogawa et al., 2002), so it is unsurprising that we saw few mature
neurons at our earlier time point. By 12 weeks post-injury, we did
observe an increase in NeuN staining densities across conditions with a
significant increase in the percentage of EGFP+ cells
co-staining for NeuN+ cells observed in conditions
that received tube implants.
In a hemisection injury model, as used in the present study, all tissue
on the ipsilateral side of the injury is completely removed, thus any
axons identified histologically are attributable to post-injury
regrowth. Increasing axon density and elongation is an important factor
when designing a treatment for SCI as this will bridge the healthy
tissue rostral and caudal to the injury. Additionally, remyelination of
these new axons is important for signal propagation along axons in the
CNS, a process that is largely attributed to the myelin sheath. We
observed a significantly higher axon density at the injury in mice
receiving IL-10 lentivirus loaded tubes with E14 spinal progenitors
compared to all other experimental conditions. With that in mind, it
should be noted that sparing, plasticity, axonal growth, and
remyelination likely occurred early after implantation and
transplantation. It is suspected that by 12 weeks post-injury the
anti-inflammatory effects of the tubes and E14 spinal progenitors have
resolved. Benefits from the tubes and E14 spinal progenitors are known
to have an early impact as we previously saw in mice with E14 spinal
progenitors alone, tubes alone, and tubes with E14 spinal progenitors
had increased axonal densities and myelinated axon densities at 4 weeks
post-injury (Ciciriello et al., 2020). In this study, mice receiving E14
spinal progenitors with IL-10 lentivirus-laden tubes possibly had a
longer therapeutic regime compared to all other conditions, resulting in
the significant increase in axon density. Directly comparing densities
between conditions can be misleading if the overall context is not
considered, and this is more apparent with the myelin data. The mice
that received E14 spinal progenitors only had an average injury area of
1.10 ± 0.5 mm2 compared to the expected area of 1.75
mm2 based on the cross-sectional area of resected
tissue. These mice may have experienced some tissue collapse as there
was no biomaterial to fill the lesion, effectively lowering the area to
which cell counts are normalized and artificially inflating densities.
Axonal remyelination results in the E14 spinal progenitor only condition
indicate they had significantly improved remyelination compared to other
conditions, but this might be attributable to a lower cross-sectional
area resulting in a higher apparent density. This discrepancy is also
highlighted when comparing axon myelination to functional data. The E14
only condition had the most myelin of all the conditions, but it was the
last treatment group to reach significantly more successful placements
compared to the SCI only group. This disparity between histological and
functional data raises a point of disconnect that could possibly be
attributable to improper synapse formation or poor myelin quality, which
could be investigated to better understand this relationship.
Conclusion
Stem cell transplantations are a promising therapy across tissue
engineering, especially in CNS damage and disease. Unfortunately,
therapeutic effect is minimized by poor survival resulting from poor
flexibility in transplantation strategies, subjecting the cells to
inhospitable conditions upon injection. Biomaterials and therapeutic
factors can facilitate improved conditions, but they are often
delivered simultaneously with cell transplants, limiting the perceived
immunomodulatory effect on the cells. In this study, our hydrogel tube
system affords temporal independence between cell transplantation and
biomaterial implantation, an advantage absent in many other
cell-biomaterial strategies. In addition to temporal independence, we
enhanced the passive immunomodulatory properties of our hydrogel tube
system with active immunomodulation via IL-10 encoding lentivirus
release from the tubes. In a 2 week course of combined passive and
active immunomodulation prior to transplantation, the IL-10 lentivirus
loaded tubes effectively created a privileged cell transplantation
site for E14 spinal progenitors. To that end, we observed a
significant increase in transplant survival and axon elongation in
addition to a more rapid functional recovery. Altogether, this therapy
synergizes the therapeutic benefits of biomaterials, stem cells, and
therapeutic factor delivery, representing a combinatorial approach
capable of addressing several of the challenges that limit recovery
post-SCI.
Supporting Information: Additional supporting information may
be found in the online version of this article.
Figure S1: IL-10 expression at 4 and 12 weeks
Figure S2: PEG implants facilitate tissue ingrowth
Figure S3: Glial scarring is decreased in mice receiving tubes
Figure S4: Exogenous progenitor characterization at 4 weeks
Figure S5: Endogenous progenitor characterization at 4 weeks
Figure S6: Ipsilateral tissue area is lower in conditions not
receiving PEG implants
Figure S7: Remyelinated axons have Schwann cell derived myelin
Data Availability: The datasets generated during and/or
analyzed during the present study are available from the corresponding
author upon reasonable request.
Conflict of Interest: The authors declare no conflicts of
interest.
Author Contributions: Study design – AJC, DRS, LDS, CMD; Data
collection – AJC, DRS, MKM, CMD; Data analysis – AJC, DRS, MKM, SJB,
CMD; Manuscript drafting – AJC, CMD; Revising and approving final
manuscript – AJC, DRS, MKM, SJB, LDS, CMD